Diagnosis and treatment of pulmonary lymphoepithelioma-like carcinoma:A case report  

作　　者：Feng-Ling Huang Min Luo Zhen-Mei He Yong-Qi Shen Guan-Da Liu 

机构地区：[1]Department of Pharmacology and Clinical Pharmacy,Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Nanning 530000,Guangxi Zhuang Autonomous Region,China [2]Department of Oncology,The Third Affiliated Hospital of Guangxi College Traditional Chinese Medicine,Liuzhou 545007,Guangxi Zhuang Autonomous Region,China

出　　处：《World Journal of Clinical Oncology》2025年第4期337-342,共6页世界临床肿瘤学杂志(英文)

基　　金：Supported by Chinese Medicine Administration Bureau of Guangxi Zhuang Autonomous Region,No.GXZYB20220472.

摘　　要：BACKGROUND Pulmonary lymphoepithelioma-like carcinoma(PLELC)is a rare primary epithelial lung cancer associated with the Epstein-Barr virus.Standard treatment guideline for PLELC is yet not to be established,surgery remains the primary treatment for early-stage PLELC,and platinum chemotherapy is the most common first-line treatment for advanced PLELC.While targeted therapy and immunotherapy has emerged as effective way to treat various malignant tumors,including lung cancer,reports on PLELC are relatively scarce.CASE SUMMARY A 38-year-old man was diagnosed with right PLELC.Chest computed tomography(CT)revealed a mass in the medial segment of the middle lobe of the right lung,with lymph node metastasis in the mediastinum and right hilum of the lung.CT-guided lung tumor biopsy was performed and the postoperative pathological examination combined with immune phenotype analysis and in situ hybridization confirmed PLELC.Standard molecular testing for patients with non-small cell lung cancer was negative and programmed cell death ligand-1 expression was about 2%.The patient declined radiotherapy and chemotherapy.Consequently,immunotherapy was administered,which included toripalimab 240 mg on day 1 and anlotinib 10 mg on days 1-14 for 10 cycles,followed by a maintenance dose of anlotinib 10 mg daily every 3 weeks.As a result,his progression-free survival reached 48 months.CONCLUSION A combination of toripalimab and anlotinib may benefit patients with advanced diseases who have not received systematic antitumor therapy.

关 键 词：Pulmonary lymphoepithelioma-like carcinoma Epstein-Barr virus Anlotinib Toripalimab Case report 

分 类 号：R73[医药卫生—肿瘤]